Novo Nordisk

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases. The projects, from Boston University, Harvard University in collaboration with Mass General Brigham, … Read the full press release →

(IN BRIEF) Research published in the European Heart Journal reveals that combining anticoagulants with NSAIDs, such as ibuprofen, diclofenac, or naproxen, significantly increases the risk of internal bleeding. The study, involving over 51,000 patients in Denmark, found that the bleeding … Read the full press release →

(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The trial involved 9,650 … Read the full press release →

(IN BRIEF) Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). If approved, Alhemo® will become the first once-daily subcutaneous prophylactic treatment for people aged 12 … Read the full press release →

(IN BRIEF) Novo Nordisk has launched the Childhood Obesity Prevention Initiative, aimed at combating rising obesity rates among children in underserved urban communities across six cities worldwide. Backed by an investment of over 250 million Danish kroner and a coalition … Read the full press release →

(IN BRIEF) Britt Meelby Jensen, the CEO of Ambu A/S, is nominated to join the Board of Directors at Hempel A/S, replacing Susanna Schneeberger. With over two decades of experience in the life science industry, including leadership roles at global … Read the full press release →

(IN BRIEF) EQT Life Sciences proudly announces Novo Nordisk’s acquisition of Cardior Pharmaceuticals, valuing the biopharmaceutical company at up to EUR 1.025 billion. Based in Hannover, Germany, Cardior specializes in RNA-based therapeutics for cardiovascular diseases, focusing initially on heart failure. … Read the full press release →

(IN BRIEF) Novo Nordisk is conducting a Capital Markets Day (CMD) to provide updates on its Strategic Aspirations 2025. The event will focus on various aspects, including corporate strategy, sustainability, research and development pipeline, and financial performance. Highlights include discussions … Read the full press release →

(IN BRIEF) Novo Nordisk has announced promising headline results from the kidney outcomes trial FLOW, which compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard care for people with type 2 diabetes and chronic kidney disease (CKD). … Read the full press release →

(IN BRIEF) Novo Nordisk A/S has announced the date for its Annual General Meeting, scheduled for Thursday, March 21, 2024, at 14:00 CET. The meeting will be held partially electronically, allowing shareholders to participate either in person at Bella Center … Read the full press release →

(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a 4% year-on-year growth in net sales driven by the strong performance of its European Dermatology business. The company’s total EBITDA … Read the full press release →

(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release →

(IN BRIEF) Novo Nordisk has announced separate research collaborations with Omega Therapeutics and Cellarity Inc. to explore innovative treatment approaches for obesity and MASH (Metabolic Associated Fatty Liver Disease). The collaboration with Omega aims to develop an epigenomic controller to … Read the full press release →